Amit Chhabra, MD
Cardiovascular Disease · Scarsdale, NYNPI 1902005622
Payments from drug & device makers
Across 367 payments — averaging $35.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$2K
- Biotronik Inc.$2K
- Boehringer Ingelheim$2K
- Boston Scientific$1K
- Novo Nordisk$695
- AOP Health US, LLC$612
- plus $5K from 28 others
What the payments were for
- Travel & lodging$7896%
- Food & beverage$12,38694%
- Education$190%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 36 | $2,225 |
| Biotronik Inc. | 30 | $1,820 |
| Boehringer Ingelheim | 47 | $1,607 |
| Boston Scientific | 29 | $1,103 |
| Novo Nordisk | 27 | $695 |
| AOP Health US, LLC | 1 | $612 |
| Abbott | 13 | $596 |
| Amgen | 20 | $567 |
| Novartis | 30 | $533 |
| Merck | 19 | $418 |
| Pfizer | 23 | $304 |
| Esperion Therapeutics, Inc. | 18 | $294 |
| Irhythm Technologies, Inc. | 6 | $274 |
| Scpharmaceuticals Inc. | 7 | $253 |
| Bridgebio Pharma, Inc. | 5 | $233 |
| Johnson & Johnson | 11 | $231 |
| Edwards Lifesciences | 2 | $194 |
| Heartflow, Inc. | 2 | $185 |
| Inspire Medical Systems, Inc. | 1 | $145 |
| AstraZeneca | 7 | $136 |
| Bristol Myers Squibb | 6 | $132 |
| United Therapeutics Corporation | 1 | $125 |
| E.r. Squibb & Sons, L.L.C. | 6 | $99 |
| Lilly USA, LLC | 5 | $99 |
| Lexicon Pharmaceuticals, Inc. | 3 | $66 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $62 |
| Alnylam Pharmaceuticals Inc. | 2 | $54 |
| Philips North America LLC | 1 | $24 |
| American Regent | 1 | $21 |
| Bayer | 1 | $19 |
| Ironwood Pharmaceuticals, Inc | 1 | $19 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $19 |
| GSK | 1 | $15 |
| Opsens Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Rapiblyk$1,225
- BioMonitor$882
- JARDIANCE$746
- Edora$470
- Acticor$470
- Solia$470
- Rivacor$470
- Reveal LINQ$399
- LINQ II$311
- JOT DX$281
- SAPIEN 3 Ultra RESILIA$178
- Cobalt$174
- WATCHMAN FLX$148
- Attruby$146
- FFRct$145
- Inspire$145
- LUX-Dx Insertable Cardiac Monitor$138
- Repatha$125
- Wegovy$125
- Watchman$123
How this compares
$13,193 in reported general payments places this provider in the 80th percentile of 2,302 cardiovascular disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 78 | $86,707 |
| EntrestoSacubitril/Valsartan | 44 | $70,603 |
| JardianceEmpagliflozin | 40 | $53,393 |
| XareltoRivaroxaban | 22 | $21,364 |
| Praluent PenAlirocumab | 20 | $13,619 |
| Metoprolol Succinate | 176 | $2,531 |
| Atorvastatin Calcium | 121 | $1,392 |
| Amlodipine Besylate | 181 | $1,065 |
| Losartan Potassium | 95 | $758 |
| Ezetimibe | 30 | $658 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 20 | $633 |
| Rosuvastatin Calcium | 41 | $583 |
| Potassium Chloride | 11 | $525 |
| Amiodarone Hcl | 14 | $513 |
| Carvedilol | 67 | $496 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $304 | $86,70778 claims |
| NovartisEntresto | $533 | $70,60344 claims |
| Boehringer IngelheimJardiance | $1,607 | $53,39340 claims |
| Johnson & JohnsonXarelto | $231 | $21,36422 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,302 cardiovascular disease providers in New York.
Other cardiovascular disease in Scarsdale
- James MinNew York$41.1M
- Robert RosensonNew York$6.9M
- Roxana MehranNew York$6.4M
- Roger HajjarNew York$5.2M
- Philippe GenereuxNew York$4.4M
- Vijay IyerAmherst$4.3M
- Gregg StoneNew York$3.7M
- Szilard VorosStony Brook$3.7M
- Valentin FusterNew York$2.9M
- Sean DonahoeRiverhead$2.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.